Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMPS | P49915 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 12/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311203 | 0.93 | DOT1L (0.38) | GMPSPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21311199 | 0.93 | GMPS (0.35) | GMPSPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21311401 | 0.92 | DOT1L (0.36) | GMPSPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20097182 | 0.91 | GMPS (0.35) | GMPSDOT1LADORA3ADORA2ASLC28A1 | |
| SCHEMBL21311196 | 0.88 | DOT1L (0.34) | GMPSDOT1LADORA3ADORA2ASLC28A1 | |
| SCHEMBL21311200 | 0.86 | NNMT (0.34) | GMPSADORA3ADORA2ASLC28A1 | |
| SCHEMBL21311209 | 0.86 | DOT1L (0.38) | GMPSDOT1L | |
| SCHEMBL21311198 | 0.84 | NNMT (0.34) | GMPSPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20096951 | 0.84 | DOT1L (0.36) | DOT1LPRMT5WDR77 | |
| SCHEMBL21311192 | 0.83 | DOT1L (0.37) | GMPSPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | GMPS 847/4885PI4KA 1441/4885PI4K2B 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.